Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.05
VRX's Cash to Debt is ranked lower than
54% of the 926 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. VRX: 0.05 )
VRX' s 10-Year Cash to Debt Range
Min: -1.06   Max: No Debt
Current: 0.05

-1.06
No Debt
Equity to Asset 0.19
VRX's Equity to Asset is ranked lower than
51% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. VRX: 0.19 )
VRX' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.85
Current: 0.19

0.18
0.85
F-Score: 7
Z-Score: 2.48
M-Score: -2.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 20.21
VRX's Operating margin (%) is ranked higher than
93% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.10 vs. VRX: 20.21 )
VRX' s 10-Year Operating margin (%) Range
Min: -9.32   Max: 45.51
Current: 20.21

-9.32
45.51
Net-margin (%) 6.23
VRX's Net-margin (%) is ranked higher than
83% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.05 vs. VRX: 6.23 )
VRX' s 10-Year Net-margin (%) Range
Min: -47.86   Max: 42.72
Current: 6.23

-47.86
42.72
ROE (%) 9.91
VRX's ROE (%) is ranked higher than
92% of the 895 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. VRX: 9.91 )
VRX' s 10-Year ROE (%) Range
Min: -59.65   Max: 88.03
Current: 9.91

-59.65
88.03
ROA (%) 1.82
VRX's ROA (%) is ranked higher than
74% of the 930 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.82 vs. VRX: 1.82 )
VRX' s 10-Year ROA (%) Range
Min: -18.92   Max: 47.04
Current: 1.82

-18.92
47.04
ROC (Joel Greenblatt) (%) 64.89
VRX's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.02 vs. VRX: 64.89 )
VRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -50.66   Max: 291.4
Current: 64.89

-50.66
291.4
Revenue Growth (3Y)(%) 46.50
VRX's Revenue Growth (3Y)(%) is ranked higher than
98% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. VRX: 46.50 )
VRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -10.8   Max: 82.1
Current: 46.5

-10.8
82.1
EBITDA Growth (3Y)(%) 113.00
VRX's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. VRX: 113.00 )
VRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -35.7   Max: 113
Current: 113

-35.7
113
EPS Growth (3Y)(%) 39.00
VRX's EPS Growth (3Y)(%) is ranked higher than
97% of the 667 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.10 vs. VRX: 39.00 )
VRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -37.2   Max: 100.6
Current: 39

-37.2
100.6
» VRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

VRX Guru Trades in Q1 2014

John Paulson 1,000,000 sh (New)
George Soros 165,411 sh (New)
Daniel Loeb 250,000 sh (New)
Chris Davis 2,718,162 sh (+2686.89%)
Diamond Hill Capital 29,370 sh (+528.24%)
Steven Cohen 8,334 sh (+276.42%)
Louis Moore Bacon 7,544 sh (+60.31%)
Lee Ainslie 2,421,778 sh (+48.23%)
Steve Mandel 8,816,702 sh (+13.67%)
Andreas Halvorsen 9,296,143 sh (+11.61%)
Jana Partners 65,500 sh (unchged)
Jeff Ubben 18,923,877 sh (unchged)
Pioneer Investments 7,300 sh (unchged)
Chuck Royce Sold Out
Jean-Marie Eveillard 902,542 sh (-0.02%)
Ruane Cunniff 34,217,366 sh (-0.26%)
Lou Simpson 1,614,593 sh (-2.65%)
Glenn Greenberg 5,592,558 sh (-8.52%)
Wallace Weitz 1,597,540 sh (-13.61%)
Private Capital 303,536 sh (-17.94%)
Jeremy Grantham 152,647 sh (-38.47%)
Mariko Gordon 24,276 sh (-45.69%)
Jim Simons 47,189 sh (-87.04%)
» More
Q2 2014

VRX Guru Trades in Q2 2014

Joel Greenblatt 6,172 sh (New)
Louis Moore Bacon 127,422 sh (+1589.05%)
Diamond Hill Capital 147,867 sh (+403.46%)
George Soros 472,187 sh (+185.46%)
Andreas Halvorsen 11,830,932 sh (+27.27%)
Chris Davis 3,153,748 sh (+16.03%)
Steve Mandel 10,089,450 sh (+14.44%)
Jean-Marie Eveillard 1,024,402 sh (+13.5%)
Lee Ainslie 2,625,014 sh (+8.39%)
Glenn Greenberg 6,050,442 sh (+8.19%)
Ruane Cunniff 34,298,384 sh (+0.24%)
Lou Simpson 1,615,549 sh (+0.06%)
Steven Cohen 1,528,606 sh (unchged)
Jeff Ubben 18,923,877 sh (unchged)
Jim Simons Sold Out
Mariko Gordon Sold Out
Daniel Loeb Sold Out
Pioneer Investments Sold Out
Private Capital 300,446 sh (-1.02%)
Wallace Weitz 1,551,076 sh (-2.91%)
John Paulson 500,300 sh (-49.97%)
Jeremy Grantham 45,552 sh (-70.16%)
» More
Q3 2014

VRX Guru Trades in Q3 2014

Jana Partners 1,284,184 sh (New)
Paul Tudor Jones 6,826 sh (New)
George Soros 626,748 sh (+32.73%)
Diamond Hill Capital 173,012 sh (+17.01%)
Lou Simpson 1,815,916 sh (+12.4%)
Chris Davis 3,529,237 sh (+11.91%)
Wallace Weitz 1,691,525 sh (+9.05%)
Steve Mandel 10,985,940 sh (+8.89%)
Glenn Greenberg 6,586,582 sh (+8.86%)
John Paulson 520,700 sh (+4.08%)
Ruane Cunniff 34,494,015 sh (+0.57%)
Jeff Ubben 18,923,877 sh (unchged)
Steven Cohen 523,400 sh (unchged)
Joel Greenblatt Sold Out
Private Capital 296,871 sh (-1.19%)
Jean-Marie Eveillard 1,010,802 sh (-1.33%)
Lee Ainslie 2,527,896 sh (-3.7%)
Andreas Halvorsen 9,967,690 sh (-15.75%)
Steven Cohen 1,056,700 sh (-30.87%)
Jeremy Grantham 23,705 sh (-47.96%)
Louis Moore Bacon 30,544 sh (-76.03%)
» More
Q4 2014

VRX Guru Trades in Q4 2014

Joel Greenblatt 295,632 sh (New)
Jim Simons 38,989 sh (New)
Jeremy Grantham 1,042,191 sh (+4296.5%)
Paul Tudor Jones 100,000 sh (+1364.99%)
Jana Partners 4,307,534 sh (+235.43%)
Jean-Marie Eveillard 1,191,832 sh (+17.91%)
Jeff Ubben 19,383,877 sh (+2.43%)
John Paulson 520,700 sh (unchged)
Ruane Cunniff 34,331,973 sh (-0.47%)
Chris Davis 3,508,163 sh (-0.6%)
Diamond Hill Capital 171,513 sh (-0.87%)
Lou Simpson 1,794,227 sh (-1.19%)
Private Capital 292,802 sh (-1.37%)
George Soros 606,587 sh (-3.22%)
Lee Ainslie 2,423,766 sh (-4.12%)
Glenn Greenberg 6,126,609 sh (-6.98%)
Andreas Halvorsen 9,077,007 sh (-8.94%)
Wallace Weitz 1,378,606 sh (-18.5%)
Steve Mandel 8,250,886 sh (-24.9%)
Louis Moore Bacon 14,286 sh (-53.23%)
Steven Cohen 132,300 sh (-87.48%)
» More
» Details

Insider Trades

Latest Guru Trades with VRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Glenn Greenberg 2014-12-31 Reduce -6.98%2.23%$113.56 - $146.39 $ 203.9552%6126609
Steve Mandel 2014-12-31 Reduce -24.9%1.39%$113.56 - $146.39 $ 203.9552%8250886
Wallace Weitz 2014-12-31 Reduce -18.5%1.2%$113.56 - $146.39 $ 203.9552%1378606
Andreas Halvorsen 2014-12-31 Reduce -8.94%0.47%$113.56 - $146.39 $ 203.9552%9077007
Jeff Ubben 2014-12-31 Add 2.43%0.41%$113.56 - $146.39 $ 203.9552%19383877
Joel Greenblatt 2014-12-31 New Buy0.34%$113.56 - $146.39 $ 203.9552%295632
Lee Ainslie 2014-12-31 Reduce -4.12%0.2%$113.56 - $146.39 $ 203.9552%2423766
Lou Simpson 2014-12-31 Reduce -1.19%0.11%$113.56 - $146.39 $ 203.9552%1794227
Ruane Cunniff 2014-12-31 Reduce -0.47%0.11%$113.56 - $146.39 $ 203.9552%34331973
Glenn Greenberg 2014-09-30 Add 8.86%2.6%$106.73 - $130.26 $ 203.9572%6586582
Andreas Halvorsen 2014-09-30 Reduce -15.75%1.02%$106.73 - $130.26 $ 203.9572%9967690
Lou Simpson 2014-09-30 Add 12.4%1.01%$106.73 - $130.26 $ 203.9572%1815916
Wallace Weitz 2014-09-30 Add 9.05%0.54%$106.73 - $130.26 $ 203.9572%1691525
Steve Mandel 2014-09-30 Add 8.89%0.46%$106.73 - $130.26 $ 203.9572%10985940
Lee Ainslie 2014-09-30 Reduce -3.7%0.18%$106.73 - $130.26 $ 203.9572%2527896
Chris Davis 2014-09-30 Add 11.91%0.15%$106.73 - $130.26 $ 203.9572%3529237
George Soros 2014-09-30 Add 32.73%0.15%$106.73 - $130.26 $ 203.9572%626748
Ruane Cunniff 2014-09-30 Add 0.57%0.14%$106.73 - $130.26 $ 203.9572%34494015
Joel Greenblatt 2014-09-30 Sold Out 0.01%$106.73 - $130.26 $ 203.9572%0
Glenn Greenberg 2014-06-30 Add 8.19%2.33%$116.99 - $138.13 $ 203.9560%6050442
Andreas Halvorsen 2014-06-30 Add 27.27%1.39%$116.99 - $138.13 $ 203.9560%11830932
Steve Mandel 2014-06-30 Add 14.44%0.64%$116.99 - $138.13 $ 203.9560%10089450
Daniel Loeb 2014-06-30 Sold Out 0.48%$116.99 - $138.13 $ 203.9560%0
Lee Ainslie 2014-06-30 Add 8.39%0.37%$116.99 - $138.13 $ 203.9560%2625014
John Paulson 2014-06-30 Reduce -49.97%0.32%$116.99 - $138.13 $ 203.9560%500300
George Soros 2014-06-30 Add 185.46%0.29%$116.99 - $138.13 $ 203.9560%472187
Wallace Weitz 2014-06-30 Reduce -2.91%0.19%$116.99 - $138.13 $ 203.9560%1551076
Chris Davis 2014-06-30 Add 16.03%0.17%$116.99 - $138.13 $ 203.9560%3153748
Mariko Gordon 2014-06-30 Sold Out 0.13%$116.99 - $138.13 $ 203.9560%0
Joel Greenblatt 2014-06-30 New Buy0.01%$116.99 - $138.13 $ 203.9560%6172
Glenn Greenberg 2014-03-31 Reduce -8.52%2.5%$112.62 - $148 $ 203.9550%5592558
Lee Ainslie 2014-03-31 Add 48.23%1.46%$112.62 - $148 $ 203.9550%2421778
Wallace Weitz 2014-03-31 Reduce -13.61%0.99%$112.62 - $148 $ 203.9550%1597540
Private Capital 2014-03-31 Reduce -17.94%0.97%$112.62 - $148 $ 203.9550%303536
Chris Davis 2014-03-31 Add 2686.89%0.95%$112.62 - $148 $ 203.9550%2718162
John Paulson 2014-03-31 New Buy0.65%$112.62 - $148 $ 203.9550%1000000
Steve Mandel 2014-03-31 Add 13.67%0.61%$112.62 - $148 $ 203.9550%8816702
Andreas Halvorsen 2014-03-31 Add 11.61%0.53%$112.62 - $148 $ 203.9550%9296143
Daniel Loeb 2014-03-31 New Buy0.48%$112.62 - $148 $ 203.9550%250000
Lou Simpson 2014-03-31 Reduce -2.65%0.25%$112.62 - $148 $ 203.9550%1614593
George Soros 2014-03-31 New Buy0.22%$112.62 - $148 $ 203.9550%165411
Mariko Gordon 2014-03-31 Reduce -45.69%0.1%$112.62 - $148 $ 203.9550%24276
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Valeant Pharmaceuticals International Inc

Diamond Hill Capital Comments on Valeant Pharmaceuticals International Inc - Jul 25, 2014

We initiated a position in Valeant Pharmaceuticals International, Inc., (VRX) a specialty pharmaceutical company that is a leader in eye care and dermatology. Unlike most in the pharmaceutical space, Valeant has a very lean cost structure and a much more targeted focus for internal research and development. Instead, the company has been very successful in acquiring proven products. Management is among the best in the business, making every decision through the lens of shareholder value creation.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Sequoia Fund's Discussion of Valeant Pharmaceuticals - Mar 07, 2014

Our largest holding, Valeant, had an outstanding year. Full year numbers have not been reported yet, but we believe that cash earnings per share should exceed $6, well ahead of last year’s result. The big news of the year was the acquisition of Bausch & Lomb for nearly $9 billion in August. The deal should be highly accretive and, together with modest organic growth in its other operations, enable cash earnings per share to increase significantly in 2014. The integration of Bausch & Lomb appears on track with cost synergies, originally estimated by management at around $800 million, now expected to be over $850 million.



Cash earnings per share have probably more than tripled over the last four years. While we do not expect this growth trajectory to continue at such a rapid pace in the future, we do believe the company can continue to produce positive organic growth supplemented by ongoing acquisitions that will enable Valeant to grow cash earnings per share at an above-average rate.



We like Valeant’s approach to the pharmaceutical business. It has acquired a diverse stable of branded, generic and OTC drugs and, more recently, medical devices including dermal fillers and contact lenses. Many of its products are steady sellers in specialty categories like dermatology and ophthalmology. In our view, Valeant is essentially a value investor in health care products.





Source: Sequoia Fund's 2013 Annual Report - Management's Discussion of Fund Performance



Check out Sequoia Fund latest stock trades

Wallace Weitz Comments on Valeant Pharmaceuticals - Jul 15, 2013

Valeant (VRX--$86)(VRX) Valeant Pharmaceuticals continues to make acquisitions (most recently agreeing to purchase Bausch and Lomb), wring cost savings from the combined operations, and grow earnings per share. The outlook for Valeant’s well-diversified portfolio of 1,100 products is relatively predictable. The company has a robust pipeline of acquisition candidates and we expect Valeant to build on its dermatology and eye care franchises over the next few years.

From Wallace Weitz’s second quarter 2013 letter to shareholders.


Check out Wallace Weitz latest stock trades

Top Ranked Articles about Valeant Pharmaceuticals International Inc

Jeff Ubben Deals in Only Four Companies in Fourth Quarter
Jeff Ubben (Trades, Portfolio), founder, chief executive officer and chief investment officer of ValueAct Holding LP, made multiple buys and sells of stocks in just four companies in the fourth quarter. That isn’t typical. Normally, he buys and sells stocks in many companies in a quarter but usually once, rarely on multiple occasions. Read more...
Former Warren Buffett CIO Lou Simpson Buys Liberty Global, Valeant, U.S. Bancorp, Sells TE Connectivity
If you don’t know Lou Simpson (Trades, Portfolio), you should. He was the former investment manager at GEICO and Warren Buffett (Trades, Portfolio) spoke highly about him many times. Mr. Simpson just reported his third quarter portfolio. He buys Liberty Global PLC, Valeant Pharmaceuticals International Inc, U.S. Bancorp, Charles Schwab Corp, Brookfield Asset Management Inc, Oracle Corporation, Wells Fargo & Co, Berkshire Hathaway Inc, Crown Holdings Inc, sells TE Connectivity Ltd during the 3-months ended 09/30/2014, according to the most recent filings of his investment company, SQ Advisors, LLC. As of 09/30/2014, SQ Advisors, LLC owns 13 stocks with a total value of $2.6 billion. These are the details of the buys and sells. Read more...
Most Held Canadian Stocks of the Second Quarter
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which companies based in Canada were held by the highest number of gurus. The following five companies come from a variety of industries, are Canadian-based and are held by the largest number of gurus. Read more...
Diamond Hill Capital Comments on Valeant Pharmaceuticals International Inc
We initiated a position in Valeant Pharmaceuticals International, Inc., (VRX) a specialty pharmaceutical company that is a leader in eye care and dermatology. Unlike most in the pharmaceutical space, Valeant has a very lean cost structure and a much more targeted focus for internal research and development. Instead, the company has been very successful in acquiring proven products. Management is among the best in the business, making every decision through the lens of shareholder value creation. Read more...
Bill Ackman and Valeant Pharmaceuticals Team Up to Take Over Pharmaceutical Company Allergen
Over the past week GuruFocus Real Time Picks reported that Bill Ackman (Trades, Portfolio) made a buy into Allergen (AGN). This is the first buy into the company for Ackman, and he did so in a big way by purchasing a total of 28,878,538 shares of the company’s stock. He bought these shares at the average price of $120.89 per share on April 11, and since this buy the price per share is up 35% to $163.65. Read more...
Top Guru-Held Canadian Stocks
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see which companies based in Canada were held by the highest number of gurus. The following five companies come from a variety of industries, are Canadian-based and are held by the largest number of gurus. Read more...
Sequoia Fund Comments on Valeant Pharmaceuticals, Advance Auto Parts, Berkshire Hathaway, and Precision Castparts
Sequoia benefited greatly from two transformative acquisitions announced in 2013: Valeant’s purchase of Bausch & Lomb and Advance Auto Parts’ purchase of General Parts International. Both deals were game changers which will significantly increase these two companies’ earnings beginning in 2014. While we’ve long been partial to companies that can grow organically, Sequoia’s returns have been boosted considerably by companies that may have limited organic growth opportunities but have done smart serial acquisitions, such as Valeant Pharmaceuticals and Berkshire Hathaway. Precision Castparts has been another serial acquirer that has created great value for shareholders. Read more...
Sequoia Fund's Discussion of Valeant Pharmaceuticals
Our largest holding, Valeant, had an outstanding year. Full year numbers have not been reported yet, but we believe that cash earnings per share should exceed $6, well ahead of last year’s result. The big news of the year was the acquisition of Bausch & Lomb for nearly $9 billion in August. The deal should be highly accretive and, together with modest organic growth in its other operations, enable cash earnings per share to increase significantly in 2014. The integration of Bausch & Lomb appears on track with cost synergies, originally estimated by management at around $800 million, now expected to be over $850 million. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 158.10
VRX's P/E(ttm) is ranked higher than
71% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 48.60 vs. VRX: 158.10 )
VRX' s 10-Year P/E(ttm) Range
Min: 5.91   Max: 661.18
Current: 158.1

5.91
661.18
Forward P/E 11.90
VRX's Forward P/E is ranked higher than
96% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 58.14 vs. VRX: 11.90 )
N/A
PE(NRI) 158.10
VRX's PE(NRI) is ranked higher than
71% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 48.50 vs. VRX: 158.10 )
VRX' s 10-Year PE(NRI) Range
Min: 5.9   Max: 631.79
Current: 158.1

5.9
631.79
P/B 15.06
VRX's P/B is ranked higher than
52% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. VRX: 15.06 )
VRX' s 10-Year P/B Range
Min: 1.03   Max: 15.06
Current: 15.06

1.03
15.06
P/S 9.81
VRX's P/S is ranked higher than
62% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. VRX: 9.81 )
VRX' s 10-Year P/S Range
Min: 1.61   Max: 9.81
Current: 9.81

1.61
9.81
PFCF 58.35
VRX's PFCF is ranked higher than
87% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. VRX: 58.35 )
VRX' s 10-Year PFCF Range
Min: 2.67   Max: 281.44
Current: 58.35

2.67
281.44
POCF 44.71
VRX's POCF is ranked higher than
78% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.53 vs. VRX: 44.71 )
VRX' s 10-Year POCF Range
Min: 4.05   Max: 48.31
Current: 44.71

4.05
48.31
EV-to-EBIT 57.56
VRX's EV-to-EBIT is ranked higher than
75% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.09 vs. VRX: 57.56 )
VRX' s 10-Year EV-to-EBIT Range
Min: -5795.6   Max: 2482.6
Current: 57.56

-5795.6
2482.6
PEG 5.99
VRX's PEG is ranked higher than
93% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. VRX: 5.99 )
VRX' s 10-Year PEG Range
Min: 0.76   Max: 249.44
Current: 5.99

0.76
249.44
Current Ratio 1.40
VRX's Current Ratio is ranked higher than
60% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.36 vs. VRX: 1.40 )
VRX' s 10-Year Current Ratio Range
Min: 0.72   Max: 9.68
Current: 1.4

0.72
9.68
Quick Ratio 1.11
VRX's Quick Ratio is ranked higher than
61% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. VRX: 1.11 )
VRX' s 10-Year Quick Ratio Range
Min: 0.59   Max: 9.3
Current: 1.11

0.59
9.3
Days Inventory 144.50
VRX's Days Inventory is ranked higher than
71% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 153.90 vs. VRX: 144.50 )
VRX' s 10-Year Days Inventory Range
Min: 89.42   Max: 333.93
Current: 144.5

89.42
333.93
Days Sales Outstanding 86.21
VRX's Days Sales Outstanding is ranked higher than
71% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.97 vs. VRX: 86.21 )
VRX' s 10-Year Days Sales Outstanding Range
Min: 43.41   Max: 146.62
Current: 86.21

43.41
146.62

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 6.52
VRX's Price/DCF (Projected) is ranked higher than
79% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.24 vs. VRX: 6.52 )
VRX' s 10-Year Price/DCF (Projected) Range
Min: 0.33   Max: 11.22
Current: 6.52

0.33
11.22
Price/Median PS Value 2.51
VRX's Price/Median PS Value is ranked higher than
57% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. VRX: 2.51 )
VRX' s 10-Year Price/Median PS Value Range
Min: 0.52   Max: 5.56
Current: 2.51

0.52
5.56
Price/Peter Lynch Fair Value 6.33
VRX's Price/Peter Lynch Fair Value is ranked higher than
89% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. VRX: 6.33 )
VRX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.67   Max: 61.66
Current: 6.33

0.67
61.66
Earnings Yield (Greenblatt) 1.70
VRX's Earnings Yield (Greenblatt) is ranked higher than
75% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. VRX: 1.70 )
VRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 20.6
Current: 1.7

0.1
20.6
Forward Rate of Return (Yacktman) 49.35
VRX's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 527 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.94 vs. VRX: 49.35 )
VRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.5   Max: 50.7
Current: 49.35

2.5
50.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:VRX.Canada, BVF.Germany,
Valeant Pharmaceuticals International Inc was formed on 29th March, 1994 and was formerly known as Biovail Corporation. It is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a range of branded, generic and branded generic pharmaceuticals, over-the-counter products "OTC", and medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices, which are marketed directly or indirectly in over 100 countries. The Company operates in two segments; Developed Markets and Emerging Markets. In the Developed Markets segment, it focuses its efforts in the eye health, dermatology, and neurology therapeutic classes. The Developed Markets segment consists of four reporting units based on geography, namely; U.S., Canada and Australia, Western Europe, and Japan. In the Emerging Markets segment, it focuses on branded generics, OTC products, and medical devices. The Emerging Markets segment consists of three reporting units based on geography, namely; Central & Eastern Europe, Middle East and North Africa, Latin America, and Asia & South Africa. Its principal pharmaceutical products are; Wellbutrin XL, Xenazine, Zovirax Cream, Zovirax, Lotemax, Arestin and Prolensa. Its principal OTC products are; PreserVision, ReNu Multiplus, Ocuvite, Artelac, and CeraVe. The Company relies on a combination of contractual provisions, confidentiality policies and procedures and patent, trademark, copyright and trade secrecy laws to protect the proprietary aspects of its technology and business. Its top four geographic markets are; the U.S. and Puerto Rico, Canada, Poland and Russia. The Company competes with specialty and other pharmaceutical companies, medical device companies, biotechnology companies, OTC companies and generic manufacturers, in the U.S., Canada, the EU and in other countries in which it market its products. The principal raw materials, including active pharmaceutical ingredient, used by the Company "or its third party manufacturers" for its various products are purchased in the open market or are otherwise available from several sources. The Company is subject to extensive U.S. federal and state health care marketing and fraud and abuse regulations, such as the federal False Claims Act, federal and provincial marketing regulation in Canada and similar regulations in foreign countries in which it may conduct its business.
» More Articles for VRX

Headlines

Articles On GuruFocus.com
Valeant Pharmaceuticals Finally Zeros In On Salix Pharmaceuticals Feb 24 2015 
How Good is Your Argument? Feb 16 2015 
Three Pharma Majors In The Run To Acquire Salix Feb 16 2015 
ValueAct Holdings trades on 2014 Q4 Feb 05 2015 
Jeff Ubben Deals in Only Four Companies in Fourth Quarter Feb 05 2015 
Weekly 52-Week Highs Highlight: KR, COV, VRX, NOC Feb 01 2015 
Weitz Value Fund Q4 2014 Commentary Jan 26 2015 
New Guru Jana Partners' Newest Stock Buys Jan 22 2015 
Analysts Make Bullish Ratings in Response to Valeant’s Increased 2015 Guidance Jan 12 2015 
Wallace Weitz Buys Discovery Communications, Sells Apple in Q3 Nov 14 2014 

More From Our Partners
Can The Uptrend Continue for Valeant (VRX)? - Tale of the Tape Mar 5 2015 - ZACKS

More From Other Websites
Dealpolitik: Valeant's Negotiations With Salix a Lesson in Deal-Making Mar 05 2015
Here is How JANA Partners Returned 6.7% in February Mar 05 2015
Can The Uptrend Continue for Valeant (VRX)? - Tale of the Tape Mar 05 2015
AbbVie trumps J&J in deal for cancer drugmaker Mar 05 2015
Parsing the Salix–Valeant merger MAC clause: Part 2 Mar 04 2015
Parsing the Salix–Valeant merger MAC clause: Part 1 Mar 04 2015
Cramer: Best of biotech Mar 04 2015
Dendreon lays off 77 including CEO W. Thomas Amick Mar 03 2015
Salix Posts Wider-than-Expected Q4 Loss as Sales Slump - Analyst Blog Mar 03 2015
JANA Partners ups position in Valeant Pharmaceuticals Mar 02 2015
Updates, advisories and surprises Mar 02 2015
Salix swings to much-wider-than-expected loss as sales plummet Mar 02 2015
Mallinckrodt PLC (MNK), Pfizer Inc. (PFE): Healthcor Management’s Top 5 Health Stocks Mar 02 2015
Valeant set for $9.6bn jumbo junk sale Mar 02 2015
QLT (QLTI) Reports Wider Year-over-Year Loss in Q4 - Analyst Blog Mar 02 2015
3 Best Performing Stocks in February - Analyst Blog Mar 02 2015
The Salix–Valeant merger: Basics of Valeant Mar 02 2015
Hedge Fund Stress, Returns, & Risk Mar 02 2015
10-K for Valeant Pharmaceuticals International, Inc. Feb 27 2015
IBD 50 Stocks Outperform; Several Setups Emerge Feb 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK